Melphalan (melphalan hydrochloride) NDC 63323-760

NDC codes

FDA NDC Directory

Product NDC (as listed)63323-760Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63323-0760Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63323-760-20	63323076020	1 KIT in 1 CARTON (63323-760-20) * 10 mL in 1 VIAL, SINGLE-DOSE (63323-761-20) * 10 mL in 1 VIAL, SINGLE-USE (63323-732-10)Marketed from Dec 22, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Melphalan
Generic name (nonproprietary): melphalan hydrochloride
Dosage form: Kit
Labeler: Fresenius Kabi USA, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203393
Marketing start: Dec 22, 2017
Listing expires: Dec 31, 2027
Identifiers: Product ID 63323-760_f3373f9b-1680-411c-922f-df58a559a6aaSPL ID f3373f9b-1680-411c-922f-df58a559a6aaSPL set ID e9c2efee-173d-4795-96d8-7aae5b3a3073RxCUI 311487

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N463323076020 followed by a unit qualifier and the quantity

Package 63323-0760-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 14, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE: Melphalan hydrochloride for injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)